HC Wainwright Expects Reduced Earnings for Jade Biosciences

Jade Biosciences, Inc. (NASDAQ:JBIO) – Equities researchers at HC Wainwright cut their Q1 2026 earnings estimates for Jade Biosciences in a report released on Wednesday, March 25th. HC Wainwright analyst A. He now expects that the company will earn ($0.50) per share for the quarter, down from their previous forecast of ($0.41). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. HC Wainwright also issued estimates for Jade Biosciences’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.52) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.09) EPS.

JBIO has been the subject of several other research reports. William Blair upgraded Jade Biosciences to a “strong-buy” rating in a research report on Monday, March 9th. Wedbush restated an “outperform” rating and issued a $24.00 target price on shares of Jade Biosciences in a report on Monday, March 9th. Stifel Nicolaus set a $40.00 target price on shares of Jade Biosciences in a research note on Friday, March 6th. Lifesci Capital upgraded shares of Jade Biosciences to a “strong-buy” rating in a report on Friday, March 6th. Finally, Zacks Research cut shares of Jade Biosciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Jade Biosciences Price Performance

JBIO opened at $13.39 on Friday. The stock’s 50 day simple moving average is $14.67 and its 200 day simple moving average is $12.57. Jade Biosciences has a 1 year low of $6.57 and a 1 year high of $100.10. The firm has a market cap of $660.34 million, a price-to-earnings ratio of -2.91 and a beta of 1.03.

Jade Biosciences (NASDAQ:JBIO) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.34.

Hedge Funds Weigh In On Jade Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. purchased a new position in shares of Jade Biosciences during the second quarter valued at about $17,703,000. Geode Capital Management LLC bought a new position in Jade Biosciences in the second quarter worth about $6,759,000. Affinity Asset Advisors LLC purchased a new stake in Jade Biosciences in the second quarter worth about $653,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Jade Biosciences during the 2nd quarter valued at approximately $71,000. Finally, Legal & General Group Plc bought a new stake in Jade Biosciences during the 2nd quarter valued at approximately $29,000.

Key Jade Biosciences News

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $35.00 price target, showing continued analyst conviction and providing a clear upside reference for investors.
• Positive Sentiment: Media coverage highlights the analyst optimism (expectation of a share rise), reinforcing the bullish narrative from HC Wainwright. Jade Biosciences (NASDAQ:JBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: HC Wainwright published detailed quarterly and annual EPS forecasts for 2026–2027 (typical biotech coverage data): ~($0.50) per quarter through 2026–2027 and FY2026/FY2027 EPS around ($2.02)/($2.09). These figures are useful for financial modeling and cash‑runway assumptions.
• Negative Sentiment: HC Wainwright lowered several near‑term EPS estimates: Q1 2026 cut from ($0.41) to ($0.50), Q2 2026 from ($0.42) to ($0.50), Q3 2026 from ($0.44) to ($0.51), Q4 2026 from ($0.46) to ($0.51). Those downgrades signal weaker near‑term operating or development visibility and are a likely driver of the share weakness.
• Negative Sentiment: The firm also reduced FY estimates (FY2026 from ($1.74) to ($2.02); FY2027 from ($2.05) to ($2.09)), increasing expected losses and pressure on near‑term valuation metrics.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.